PYLERA (bismuth subcitrate potassium) · LABS JUVISE
Pylera is a fixed-dose combination therapy containing bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride. It is indicated for the treatment of patients with *Helicobacter pylori* infection and duodenal ulcer disease (either active or a history within the past 5 years). Administered in conjunction with omeprazole, this regimen is designed to eradicate *H. pylori* to reduce the risk of duodenal ulcer recurrence. In accordance with antibacterial stewardship principles, Pylera should be reserved for infections proven or strongly suspected to be caused by susceptible bacteria to prevent the development of drug resistance.
How PYLERA Works
Pylera functions through the combined action of two antibacterial agents and a bismuth salt. Metronidazole (a nitroimidazole) and tetracycline hydrochloride (a protein synthesis inhibitor) provide synergistic antimicrobial activity against *H. pylori*. Bismuth subcitrate potassium provides additional bactericidal effects and may exert cytoprotective effects on the gastric mucosa. When used with omeprazole, which increases intragastric pH, the combination optimizes the environment for bacterial eradication.
Details
- Status
- Prescription
- First Approved
- 2006-09-28
- Routes
- ORAL
- Dosage Forms
- CAPSULE
Companies
PYLERA Approval History
What PYLERA Treats
2 indicationsPYLERA is approved for 2 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Helicobacter pylori Infection
- Duodenal Ulcer
PYLERA Boxed Warning
POTENTIAL FOR CARCINOGENICITY Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans [see Warning and Precautions (5.1) ]. WARNING: POTENTIAL FOR CARCINOGENICITY See full prescribing information for complete boxed warning. Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans ( 5.1 )....
WARNING: POTENTIAL FOR CARCINOGENICITY Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans [see Warning and Precautions (5.1) ]. WARNING: POTENTIAL FOR CARCINOGENICITY See full prescribing information for complete boxed warning. Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans ( 5.1 ).
PYLERA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to PYLERA
3 of 19FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PYLERA FDA Label Details
Indications & Usage
FDA Label (PDF)PYLERA is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be c...
WARNING: POTENTIAL FOR CARCINOGENICITY Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans [see Warning and Precautions (5.1) ]. WARNING: POTENTIAL FOR CARCINOGENICITY See full prescribing information for ...
Track PYLERA with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.